Literature DB >> 24943382

Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.

Jeffrey E Teigler1, Pablo Penaloza-MacMaster1, Rebecca Obeng1, Nicholas M Provine1, Rafael A Larocca1, Erica N Borducchi1, Dan H Barouch2.   

Abstract

Hexon modification of adenovirus type 5 (Ad5) vectors with the hypervariable regions (HVRs) of Ad48 has been shown to allow Ad5HVR48 vectors to circumvent the majority of the preexisting Ad5-neutralizing antibodies. However, it remains unclear whether modifying hexon HVRs impacts innate or adaptive immune responses elicited by this vector. In this study, we investigated the influence of the HVR substitution of Ad5 on innate and adaptive immune responses following vaccination. Ad5HVR48 displayed an intermediate level of innate immune cytokines and chemokines relative to those of Ad5 and Ad48, consistent with its chimeric nature. Hepatotoxicity was observed after Ad5 immunization but not after Ad5HVR48 or Ad48 immunization. However, the CD8(+) T-cell responses elicited by Ad5HVR48 vectors displayed a partially exhausted phenotype, as evidenced by the sustained expression of programmed death 1 (PD-1), decreased effector-to-central memory conversion, and reduced memory recall responses, similar to those elicited by Ad5 vectors and in contrast to those induced by Ad48 vectors. Taken together, these results indicate that although Ad5HVR48 largely bypasses preexisting Ad5 neutralizing antibodies and shows reduced hepatotoxicity compared to that of Ad5, it induces adaptive immune phenotypes that are functionally exhausted similar to those elicited by Ad5.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943382      PMCID: PMC4135912          DOI: 10.1128/CVI.00207-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  37 in total

Review 1.  Adenovirus vectors for gene expression.

Authors:  M V Chengalvala; M D Lubeck; B J Selling; R J Natuk; K H Hsu; B B Mason; P K Chanda; R A Bhat; B M Bhat; S Mizutani
Journal:  Curr Opin Biotechnol       Date:  1991-10       Impact factor: 9.740

Review 2.  Adenovirus-based genetic vaccines for biodefense.

Authors:  Julie L Boyer; Gary Kobinger; James M Wilson; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2005-02       Impact factor: 5.695

3.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

4.  FX and host defense evasion tactics by adenovirus.

Authors:  Andrew H Baker; Stuart A Nicklin; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

5.  Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.

Authors:  Neus Bayo-Puxan; Manel Cascallo; Alena Gros; Meritxell Huch; Cristina Fillat; Ramon Alemany
Journal:  J Gen Virol       Date:  2006-09       Impact factor: 3.891

6.  Blood clearance rates of adenovirus type 5 in mice.

Authors:  Ramon Alemany; Kaori Suzuki; David T Curiel
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

7.  Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues.

Authors:  L Crawford-Miksza; D P Schnurr
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Authors:  Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-11-16       Impact factor: 25.606

10.  Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats.

Authors:  Campbell G Nicol; Delyth Graham; William H Miller; Stephen J White; Theodore A G Smith; Stuart A Nicklin; Susan C Stevenson; Andrew H Baker
Journal:  Mol Ther       Date:  2004-08       Impact factor: 11.454

View more
  8 in total

1.  Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum.

Authors:  Andrew W Harmon; Rituparna Moitra; Zhili Xu; Andrew P Byrnes
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

2.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

3.  Binding of adenovirus species C hexon to prothrombin and the influence of hexon on vector properties in vitro and in vivo.

Authors:  Jie Tian; Zhili Xu; Rituparna Moitra; Donna J Palmer; Philip Ng; Andrew P Byrnes
Journal:  PLoS Pathog       Date:  2022-09-26       Impact factor: 7.464

4.  A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Authors:  Jairo Andres Fonseca; Monica Cabrera-Mora; Elena A Kashentseva; John Paul Villegas; Alejandra Fernandez; Amelia Van Pelt; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

Review 5.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

6.  Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.

Authors:  Pablo Penaloza-MacMaster; Quazim A Alayo; Joshua Ra; Nicholas M Provine; Rafael Larocca; Benjamin Lee; Dan H Barouch
Journal:  Vaccine       Date:  2016-08-24       Impact factor: 3.641

Review 7.  Novel Concepts for HIV Vaccine Vector Design.

Authors:  Quazim A Alayo; Nicholas M Provine; Pablo Penaloza-MacMaster
Journal:  mSphere       Date:  2017-12-06       Impact factor: 4.389

8.  Immunoinformatic construction of an adenovirus-based modular vaccine platform and its application in the design of a SARS-CoV-2 vaccine.

Authors:  Pedro Soares Porto; Déborah Anjos; Nathânia Dábilla; Simone Gonçalves da Fonseca; Menira Souza
Journal:  Infect Genet Evol       Date:  2020-08-03       Impact factor: 3.342

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.